Business
Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing
About this update from Indaptus Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has received a patent allowance on Application #1120150158323 from the National Institute of Industrial Property of Brazil for its Decoy immunotherapy platform. The allowed patent includes a disease agnostic independent composition claim covering the Decoy platform. Jeffrey Meckler, Indaptus’ CEO commented, “We are pleased with the increasing global reach of the patents being issued for our Decoy platform, with most major countries now having granted patents. We expect to continue to strengthen our intellectual property estate for the Decoy platform, providing additional value for shareholders. In the meantime, we continue to enroll our Phase 1 INDP-D101 trial in solid tumors and look forward to providing updates on those results as data becomes available for release.” About Indaptus Therapeutics Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR) agonist Decoy platform. The products are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy products represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy products in combination with anti-PD-1 checkpoint therap...